Yuri Khodjamirian, fund manager at Tema ETFs, says there's a 'valuation opportunity' in biotech stocks at the moment — but also warned of risks.
Weight loss drugs have drawn investor interest and shaken up other sectors in the past year or so. Novo Nordisk and Eli Lilly were two early winners of this trend, as their drugs dominate the weight loss drug market. Yuri Khodjamirian, fund manager at Tema ETFs, said both companies are a "very powerful duopoly." "But there's obviously going to be room ins such a big market. The estimates currently are about $130 billion from Goldman Sachs.
He also named smaller biotech firms such as Zealand Pharma and Viking Therapeutics . "These companies are early biotechs that are developing data. They're a lot more risky than the bigger ones who already have drugs on the market," Khodjamirian said. "And therefore, you have to just be very careful with making investments in such companies. So a diversified portfolio is probably the best way to go," he said.
Biotech And Pharmaceuticals Viking Therapeutics Inc Zealand Pharma A/S Zealand Pharma A/S Roche Holding AG Carmot Therapeutics Inc Eli Lilly And Co Novo Nordisk A/S Amgen Inc Exchange-Traded Funds Business News
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Intel, Nvidia, Eli Lilly rise premarket; BP, Novo Nordisk fallIntel, Nvidia, Eli Lilly rise premarket; BP, Novo Nordisk fall
Read more »
Novo Nordisk stock price falls after Eli Lilly weight loss drug outperforms OzempicPolitical News and Conservative Analysis About Congress, the President, and the Federal Government
Read more »
Novo Nordisk and Eli Lilly shares slide on new obesity drug trial from RocheNovo Nordisk and Eli Lilly shares slid Wednesday on promising early-stage trial data from Roche's latest obesity drug candidate.
Read more »
Novo Nordisk and Eli Lilly shares slide on new obesity drug trial from RocheNovo Nordisk and Eli Lilly shares slid Wednesday on promising early-stage trial data from Roche’s latest obesity drug candidate.
Read more »
Wednesday's analyst calls: Eli Lilly gets a price target increase, Goldman sees Tesla declineTesla and a pharmaceutical giant were among the stocks analysts were talking about on Wednesday.
Read more »
Billionaire Harvard Professor’s Fortune Jumps Nearly $200 Million On News Of Eli Lilly Biotech DealGiacomo Tognini is a Staff Writer on the Wealth team at Forbes, covering billionaires and their wealth. He joined Forbes in 2019 and lives in New York.
Read more »